Sales & Marketing News | pharmaphorum

News

Teva will appeal opioid liability ruling in New York trial

The jury in a new York trial has found that Teva Pharmaceuticals played a role in fuelling the opioid crisis in the US, and should

News

Leo puts target on Dupixent in US as FDA clears tralokinumab

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.

News

Novartis bags elusive US approval for cholesterol drug incli...

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year.

News

Amgen builds Otezla's psoriasis label as rival BMS looms lar...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, w

News

Biogen takes axe to Aduhelm price in a bid to drive take-up

Biogen has cut the list price of its Alzheimer's disease therapy in half from $56,000 to $28,200 a year, before the outcome of an ongoing reimbursement review of the drug by the US governme

News